Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR2554 + liposomal mitoxantrone
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral, Intravenous
01
Overview
SHR2554 + liposomal mitoxantrone is an investigational combination therapy being evaluated for the treatment of peripheral T-cell lymphoma (PTCL). SHR2554 is an oral, small-molecule inhibitor of Enhancer of Zeste Homolog 2 (EZH2), a histone methyltransferase that plays a key role in epigenetic regulation and is often overexpressed or mutated in various lymphomas. Liposomal mitoxantrone is a nanoparticle-encapsulated formulation of the anthracenedione chemotherapy agent mitoxantrone, which acts by intercalating into DNA and inhibiting topoisomerase II, thereby inducing DNA damage and cell death. The combination aims to provide synergistic anti-tumor activity by combining targeted epigenetic modulation with potent cytotoxic chemotherapy delivered via a liposomal carrier.
- Other names
- SHR2554 and liposomal mitoxantroneSHR-2554 and liposomal mitoxantroneSHR 2554 and liposomal mitoxantroneSHR2554 combined with Liposomal MitoxantroneSHR-2554 combined with Liposomal MitoxantroneSHR 2554 combined with Liposomal Mitoxantrone
02
Targets
DNATOP2A (DNA topoisomerase II)EZH2 (Histone-lysine N-methyltransferase EZH2)
Beyond the preview
Go deeper on SHR2554 + liposomal mitoxantrone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR2554 + liposomal mitoxantrone.